Company Filing History:
2 out of 1,343 
2 out of 1,289 
Years Active: 1993-1995
Title: David Edgar: Innovator in Neurotrophic Factor Research
Introduction
David Edgar is a notable inventor based in Liverpool, GB. He has made significant contributions to the field of neurobiology, particularly through his work on brain-derived neurotrophic factor (BDNF). With a total of 2 patents, his innovations have the potential to impact therapeutic approaches for neurodegenerative diseases.
Latest Patents
One of David Edgar's latest patents focuses on nucleic acid sequences encoding brain-derived neurotrophic factor (BDNF). This invention details the production of BDNF protein in substantial quantities, which is crucial for clinical applications. The patent also discusses pharmacologic compositions and therapeutic uses of BDNF, highlighting its role in promoting the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons. This advancement offers a promising method for treating Parkinson's disease and Alzheimer's disease. Additionally, the invention includes antibodies directed toward BDNF or its fragments, providing a method for generating sufficient immunogen. By comparing the nucleic acid sequences of BDNF and nerve growth factor (NGF), the invention identifies homologous regions, thereby defining a BDNF/NGF gene family and facilitating the identification of additional members of this gene family.
Career Highlights
Throughout his career, David Edgar has worked with prominent organizations such as Regeneron Pharmaceuticals, Inc. and the Max Planck Society for the Advancement of Science. His experience in these institutions has contributed to his expertise in neurotrophic factors and their applications in medicine.
Collaborations
David has collaborated with esteemed colleagues, including Yves-Alain Barde and Joachim Leibrock. These partnerships have further enriched his research and innovation in the field.
Conclusion
David Edgar's work in the development of brain-derived neurotrophic factor represents a significant advancement in neurobiology. His patents and collaborations highlight his commitment to improving therapeutic strategies for neurodegenerative diseases.